Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Branched-chain alpha-ketoacid dehydrogenase complex E1 (BCKDH E1) is the rate-limiting enzyme component of the mitochondrial BCKDH multienzyme complex [1, 2]. It catalyzes the oxidative decarboxylation of branched-chain alpha-keto acids (BCKAs) derived from the essential amino acids leucine, isoleucine, and valine [3]. The E1 component is a heterotetramer composed of two alpha (BCKDHA) and two beta (BCKDHB) subunits and requires thiamine pyrophosphate (TPP) as a vital cofactor [1, 2]. Genetic mutations in the E1 subunits lead to Maple Syrup Urine Disease (MSUD), a condition characterized by the toxic accumulation of branched-chain amino acids (BCAAs) and their ketoacid derivatives, which can cause severe neurological damage [3]. In addition to its role in rare genetic disorders, BCKDH activity is increasingly recognized as a factor in metabolic health, where its suppression is linked to insulin resistance, obesity, and heart failure [5]. Therapeutic strategies include high-dose thiamine for responsive MSUD variants and the use of kinase inhibitors like phenylbutyrate to maintain the complex in its active, dephosphorylated state [4]. Sources: [1] UniProt Consortium. P12694 (BCKDHA). [2] UniProt Consortium. P21953 (BCKDHB). [3] StatPearls. Maple Syrup Urine Disease. [4] Brunetti-Pierri N, et al. (2011). Phenylbutyrate therapy for maple syrup urine disease. Human Molecular Genetics. [5] Tso SC, et al. (2014). Structural Basis for the Allosteric Inhibition of the BCKDH Kinase by a Novel Small Molecule. Journal of Biological Chemistry.
Cofactor supplementation (Thiamine) to enhance enzyme activity in responsive mutations; inhibition of branched-chain alpha-ketoacid dehydrogenase kinase (BCKDK) by drugs like phenylbutyrate to prevent the phosphorylation-mediated inactivation of the E1 subunit, thereby increasing overall complex activity.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Branched-chain alpha-ketoacid dehydrogenase complex E1 (BCKDH E1).